Correction to: Current scenario and future strategies to fight artemisinin resistance

Pasupureddy, Rahul; Atul, Atul; Seshadri, Sriram; Pande, Veena; Dixit, Rajnikant; Pandey, Kailash C.

doi:10.1007/s00436-018-6175-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the Plasmodium parasites have developed resistance against the most commonly used antimalarial drugs throughout Africa and Asia [3], especially amid concerns about the spread of artemisinin resistance over the last five years. This process may accelerate in the future [4,5]. The international malaria community urges new strategies and next-generation drugs to control malaria.…”

Section: Introductionmentioning

confidence: 99%

Fungal Metabolite Asperaculane B Inhibits Malaria Infection and Transmission

et al. 2020

View full text Add to dashboard Cite

Mosquito-transmitted Plasmodium parasites cause millions of people worldwide to suffer malaria every year. Drug-resistant Plasmodium parasites and insecticide-resistant mosquitoes make malaria hard to control. Thus, the next generation of antimalarial drugs that inhibit malaria infection and transmission are needed. We screened our Global Fungal Extract Library (GFEL) and obtained a candidate that completely inhibited Plasmodium falciparum transmission to Anopheles gambiae. The candidate fungal strain was determined as Aspergillus aculeatus. The bioactive compound was purified and identified as asperaculane B. The concentration of 50% inhibition on P. falciparum transmission (IC50) is 7.89 µM. Notably, asperaculane B also inhibited the development of asexual P. falciparum with IC50 of 3 µM, and it is nontoxic to human cells. Therefore, asperaculane B is a new dual-functional antimalarial lead that has the potential to treat malaria and block malaria transmission.

show abstract

Section: Introductionmentioning

confidence: 99%